Prospective study of eukaryotic initiation factor 4E protein elevation and breast cancer outcome - PubMed (original) (raw)
Prospective study of eukaryotic initiation factor 4E protein elevation and breast cancer outcome
Benjamin D L Li et al. Ann Surg. 2002 May.
Abstract
Objective: To validate the authors' initial hypothesis-generating observation that eukaryotic initiation factor 4E (eIF4E) protein elevation predicts a higher cancer recurrence rate in patients with stage 1 to 3 breast cancer.
Summary background data: Tumor size and nodal status continue to be the two most important independent prognostic markers in breast cancer, despite well-documented limitations. In a previous smaller retrospective study, eIF4E, important in the regulation of protein synthesis of mRNAs with long or complex 5' untranslated regions, appeared promising as an independent predictor of breast cancer recurrence.
Methods: Specimens and clinical data from 191 patients with stage 1 to 3 breast cancer were accrued prospectively. Data collected include stage of disease, tumor grade, age at diagnosis, and menopausal status. Endpoints measured were disease recurrence and cancer-related death. eIF4E protein level was quantified using Western blot analysis. Immunohistochemical staining was used to determine estrogen receptor, progesterone receptor, and HER-2/neu receptor status. Statistical analysis include Cox proportional hazards model, log-rank test, Kaplan-Meier survival curve, Fisher exact test, and t test.
Results: Patients were divided into three groups based on tertile distribution of eIF4E: low, defined as less than 7.5-fold elevation (n = 64); intermediate, defined as 7.5- to 14-fold elevation (n = 61); and high, defined as more than 14-fold elevation (n = 66). The relative risk for cancer recurrence with intermediate elevation was 4.1 times that of patients with low elevation. For patients with high elevation, the relative risk for recurrence was higher, at 7.2 times that of the low group. The relative risk for cancer-related death for high elevation was 7.3 times that of patients with low eIF4E. Using multivariate analysis, high eIF4E remained an independent predictor of cancer recurrence after adjusting for tumor size, tumor grade, nodal disease, estrogen receptor status, progesterone receptor status, and menopausal status.
Conclusions: High eIF4E is an independent predictor of cancer recurrence in patients with stage 1 to 3 breast cancer. The relative risk for cancer recurrence increases with eIF4E protein elevation. High eIF4E elevation is also associated with an increased relative risk for cancer-related death.
Figures
Figure 1. A typical Western blot showing the intensity of the 25-kd eIF4E protein band in carcinoma specimens CA1 through CA5 relative to benign control and the eIF4E standard curve.
Figure 2. Tertile distribution of eIF4E overexpression.
Figure 3. Comparison of disease-free survival using the Kaplan-Meier method between the groups of patients with low, intermediate, and high eIF4E protein elevation.
Figure 4. Comparison of cancer-related death rates using the Kaplan-Meier method between the groups of patients with low, intermediate, and high eIF4E protein elevation.
Similar articles
- A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancer.
McClusky DR, Chu Q, Yu H, Debenedetti A, Johnson LW, Meschonat C, Turnage R, McDonald JC, Abreo F, Li BD. McClusky DR, et al. Ann Surg. 2005 Oct;242(4):584-90; discussion 590-2. doi: 10.1097/01.sla.0000184224.55949.90. Ann Surg. 2005. PMID: 16192819 Free PMC article. Clinical Trial. - Up-regulation of TLK1B by eIF4E overexpression predicts cancer recurrence in irradiated patients with breast cancer.
Wolfort R, de Benedetti A, Nuthalapaty S, Yu H, Chu QD, Li BD. Wolfort R, et al. Surgery. 2006 Aug;140(2):161-9. doi: 10.1016/j.surg.2006.05.001. Surgery. 2006. PMID: 16904965 - Correlation of TLK1B in elevation and recurrence in doxorubicin-treated breast cancer patients with high eIF4E overexpression.
Byrnes KW, DeBenedetti A, Holm NT, Luke J, Nunez J, Chu QD, Meschonat C, Abreo F, Johnson LW, Li BD. Byrnes KW, et al. J Am Coll Surg. 2007 May;204(5):925-33; discussion 933-4. doi: 10.1016/j.jamcollsurg.2007.02.027. J Am Coll Surg. 2007. PMID: 17481512 - A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-negative breast cancer.
Holm N, Byrnes K, Johnson L, Abreo F, Sehon K, Alley J, Meschonat C, Md QC, Li BD. Holm N, et al. Ann Surg Oncol. 2008 Nov;15(11):3207-15. doi: 10.1245/s10434-008-0086-9. Epub 2008 Aug 22. Ann Surg Oncol. 2008. PMID: 18719964 - Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Gonzalez-Angulo AM, et al. Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1. Adv Exp Med Biol. 2007. PMID: 17993229 Review.
Cited by
- Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML.
Nishida Y, Zhao R, Heese LE, Akiyama H, Patel S, Jaeger AM, Jacamo RO, Kojima K, Ma MCJ, Ruvolo VR, Chachad D, Devine W, Lindquist S, Davis RE, Porco JA Jr, Whitesell L, Andreeff M, Ishizawa J. Nishida Y, et al. Leukemia. 2021 Sep;35(9):2469-2481. doi: 10.1038/s41375-021-01308-z. Epub 2021 Jun 14. Leukemia. 2021. PMID: 34127794 Free PMC article. Review. - A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancer.
McClusky DR, Chu Q, Yu H, Debenedetti A, Johnson LW, Meschonat C, Turnage R, McDonald JC, Abreo F, Li BD. McClusky DR, et al. Ann Surg. 2005 Oct;242(4):584-90; discussion 590-2. doi: 10.1097/01.sla.0000184224.55949.90. Ann Surg. 2005. PMID: 16192819 Free PMC article. Clinical Trial. - Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?
Borden KL, Culjkovic-Kraljacic B. Borden KL, et al. Leuk Lymphoma. 2010 Oct;51(10):1805-15. doi: 10.3109/10428194.2010.496506. Leuk Lymphoma. 2010. PMID: 20629523 Free PMC article. Review. - eIF4E orchestrates mRNA processing, RNA export and translation to modify specific protein production.
Mars JC, Culjkovic-Kraljacic B, Borden KLB. Mars JC, et al. Nucleus. 2024 Dec;15(1):2360196. doi: 10.1080/19491034.2024.2360196. Epub 2024 Jun 16. Nucleus. 2024. PMID: 38880976 Free PMC article. Review. - Eukaryotic initiation factor 4E-binding protein 1 (4E-BP1): a master regulator of mRNA translation involved in tumorigenesis.
Musa J, Orth MF, Dallmayer M, Baldauf M, Pardo C, Rotblat B, Kirchner T, Leprivier G, Grünewald TG. Musa J, et al. Oncogene. 2016 Sep 8;35(36):4675-88. doi: 10.1038/onc.2015.515. Epub 2016 Feb 1. Oncogene. 2016. PMID: 26829052 Review.
References
- Weidner N, Cady B, Goodson WH III. Pathologic prognostic factors for patients with breast carcinoma: which factors are important. Surg Oncol Clin North Am 1997; 6: 415–453. - PubMed
- Silverstein MJ, Skinner KA, Lomis TJ. Predicting axillary nodal positivity in 2282 patients with breast carcinoma. World J Surg 2001; 25: 767–772. - PubMed
- Jatoi I, Hilsenbeck SG, Clark GM, Osborne CK. Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol 1999; 17: 2334–2340. - PubMed
- DeBenedetti A, Harris AL. EIF4E expression in tumors: its possible role in progression of malignancies. Int J Biochem Cell Biol 1999; 31: 59–72. - PubMed
- Rhoads RE, Joshi-Barve S, Rinker-Schaeffer C. Mechanism of action and regulation of protein synthesis initiation factor 4E: effects of mRNA discrimination, cellular growth rate, and oncogenesis. Prog Nucleic Acid Res Mol Biol 1993; 46: 183–219. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous